Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | BRD1 | O95696 | 2/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.31 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471275 | 1.00 | KCNH2 (0.33) | KCNH2CYP3A4CYP2D6NOS2BRD1 | |
| SCHEMBL24316893 | 0.93 | KCNH2 (0.33) | KCNH2CYP3A4CYP2D6BRD1BRPF1 | |
| SCHEMBL24316872 | 0.86 | HTR6 (0.35) | CYP3A4CYP2D6MAOA | |
| SCHEMBL24316890 | 0.82 | BRD4 (0.33) | BRD1BRPF1BRPF3BRD4BRD9 | |
| SCHEMBL29471180 | 0.82 | BRD4 (0.33) | BRD1BRPF1BRPF3BRD4BRD9 | |
| SCHEMBL24316891 | 0.81 | KDM4E (0.37) | CYP3A4CYP2D6BRD1BRPF1BRPF3 | |
| SCHEMBL29471236 | 0.81 | KDM4E (0.37) | CYP3A4CYP2D6BRD1BRPF1BRPF3 | |
| SCHEMBL30480872 | 0.81 | KDM4E (0.37) | CYP3A4CYP2D6BRD1BRPF1BRPF3 | |
| SCHEMBL24316860 | 0.81 | KDM1A (0.35) | NOS2 | |
| SCHEMBL24316858 | 0.81 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| CN-116368128-A | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | 奥瑞基尼肿瘤有限公司 | 2023-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | KCNH2 3400/4885CYP3A4 4544/4885CYP2D6 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.